Sort
48,018 grants matching “immunotherapy”
Identifying antitumor T cell receptors for cellular immunotherapy
$673,212Sri Krishna · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Multicolor PET to interrogate cancer biology
$673,118Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2025 · EB
Harnessing the nervous system to overcome resistance to immunotherapy in oral cancer
$673,034Moran Amit · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · DE
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
$672,991Daniel J. Powell · University Of Pennsylvania · R01 · FY2022 · CA
Investigating the therapeutic potential of a novel glutamine antagonist in KEAP1 mutant lung cancer
$672,853Thales Papagiannakopoulos · New York University School Of Medicine · R01 · FY2024 · CA
Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model
$672,844Seth M Pollack · Northwestern University At Chicago · R01 · FY2025 · CA
Targeting Latency Switch in EBV+ Lymphomas
$672,839Lisa Giulino Roth · Weill Medical Coll Of Cornell Univ · R37 · FY2022 · CA
Targeted cell-depleting immunotherapy for TB and HIV
$672,796William Ramses Bishai · Johns Hopkins University · R01 · FY2023 · AI
Targeted cell-depleting immunotherapy for TB and HIV
$672,796William Ramses Bishai · Johns Hopkins University · R01 · FY2021 · AI
Targeted cell-depleting immunotherapy for TB and HIV
$672,796William Ramses Bishai · Johns Hopkins University · R01 · FY2022 · AI
Targeted cell-depleting immunotherapy for TB and HIV
$672,796William Ramses Bishai · Johns Hopkins University · R01 · FY2024 · AI
Targeted cell-depleting immunotherapy for TB and HIV
$672,796William Ramses Bishai · Johns Hopkins University · R01 · FY2020 · AI
A physical sciences approach to investigate the role of exosomes in metastatic progression
$672,673Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2025 · CA
Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.
$672,634Alain Charest · Beth Israel Deaconess Medical Center · R01 · FY2023 · CA
Cancer immunotherapy
$672,569Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis
$672,512David M. Lewinsohn · Oregon Health & Science University · R01 · FY2022 · AI
Genetically engineered mouse model to improve therapy of NUT carcinoma
$672,468Christopher A French · Brigham And Women'S Hospital · R01 · FY2023 · CA
Career Development in Pediatric and Medical Oncology
$672,442Irwin Bernstein · Fred Hutchinson Cancer Research Center · K12 · FY2018 · CA
Ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics.
$672,371Etienne Caron · Yale University · R61 · FY2025 · CA
Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies
$672,300Pavlos Msaouel · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA
Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies
$672,300Pavlos Msaouel · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
$672,297David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells
$672,271Sandra Aung · Ubivac, Llc · R44 · FY2011 · CA
Evaluation of Neurobiological Mechanisms Mediating the Effect of Immune Activation on Neurocognitive Impairment and the Role of Psychosocial Factors Among Women Living with HIV
$672,268Pariya Fazeli Wheeler · University Of Alabama At Birmingham · R01 · FY2023 · MH
ISS-ODN activation of tonsillar APCs to augment immunity
$672,258Population Council · R01 · FY2004 · DE